
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of September 2015

Commission File Number 001-16174

**TEVA PHARMACEUTICAL INDUSTRIES
LIMITED**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

CONTENTS

At the 2015 Annual Meeting of Shareholders of Teva Pharmaceutical Industries Limited, which was held on September 3, 2015, all proposals were approved by the required majority of shareholders voting in person or by proxy, by the following approximate percentages of shares voting, based on a preliminary tabulation:

- Appointment of Roger Abravanel as director – 95%
- Appointment of Rosemary A. Crane as director – 93%
- Appointment of Gerald M. Lieberman as director – 93%
- Appointment of Galia Maor as director – 93%
- Appointment of Gabrielle Sulzberger as statutory independent director and approval of her remuneration and benefits – 94%
- Amendment to Compensation Policy – 81%
- Directors compensation – 82%
- Chairman compensation – 94%
- Amendment to the Terms of Office and Employment of the CEO – 94%
- Special bonus for CEO – 94%
- 2015 Equity-Based Incentive Plan – 93%
- Appointment of independent auditors – 98%

As previously announced, Teva did not use its discretionary proxy to vote uninstructed ordinary shares represented by ADSs.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Date: September 3, 2015

By: /S/ EYAL DESHEH

Name: **Eyal Desheh**

Title: **Group Executive Vice President, Chief Financial Officer**